JP6280129B2 - カルシウムフラックスアゴニスト及びその方法 - Google Patents

カルシウムフラックスアゴニスト及びその方法 Download PDF

Info

Publication number
JP6280129B2
JP6280129B2 JP2015542037A JP2015542037A JP6280129B2 JP 6280129 B2 JP6280129 B2 JP 6280129B2 JP 2015542037 A JP2015542037 A JP 2015542037A JP 2015542037 A JP2015542037 A JP 2015542037A JP 6280129 B2 JP6280129 B2 JP 6280129B2
Authority
JP
Japan
Prior art keywords
calcium flux
skin
pharmaceutical composition
ligand
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015542037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015537000A (ja
JP2015537000A5 (enExample
Inventor
ニアジ，ケイバン
ラビザデー，シャルーズ
ゴロヴァト，ジャスティン
スン—シオン，パトリック
スン―シオン，パトリック
レニー，アン—ローラ
レニー，アン―ローラ
ブズコ，オレクサンドル
Original Assignee
ナント ホールディングス アイピー，エルエルシー
ナント ホールディングス アイピー，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナント ホールディングス アイピー，エルエルシー, ナント ホールディングス アイピー，エルエルシー filed Critical ナント ホールディングス アイピー，エルエルシー
Publication of JP2015537000A publication Critical patent/JP2015537000A/ja
Publication of JP2015537000A5 publication Critical patent/JP2015537000A5/ja
Application granted granted Critical
Publication of JP6280129B2 publication Critical patent/JP6280129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2015542037A 2012-11-13 2013-11-13 カルシウムフラックスアゴニスト及びその方法 Active JP6280129B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261725881P 2012-11-13 2012-11-13
US61/725,881 2012-11-13
PCT/US2013/069939 WO2014078447A1 (en) 2012-11-13 2013-11-13 Calcium flux agonists and methods therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018006246A Division JP6625677B2 (ja) 2012-11-13 2018-01-18 カルシウムフラックスアゴニスト及びその方法

Publications (3)

Publication Number Publication Date
JP2015537000A JP2015537000A (ja) 2015-12-24
JP2015537000A5 JP2015537000A5 (enExample) 2016-12-08
JP6280129B2 true JP6280129B2 (ja) 2018-02-14

Family

ID=50731660

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015542037A Active JP6280129B2 (ja) 2012-11-13 2013-11-13 カルシウムフラックスアゴニスト及びその方法
JP2018006246A Active JP6625677B2 (ja) 2012-11-13 2018-01-18 カルシウムフラックスアゴニスト及びその方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018006246A Active JP6625677B2 (ja) 2012-11-13 2018-01-18 カルシウムフラックスアゴニスト及びその方法

Country Status (8)

Country Link
US (3) US9463184B2 (enExample)
EP (1) EP2919793B1 (enExample)
JP (2) JP6280129B2 (enExample)
KR (3) KR20150140625A (enExample)
CN (1) CN105188716B (enExample)
AU (1) AU2013344879B2 (enExample)
CA (1) CA2893276C (enExample)
WO (1) WO2014078447A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080199A (ja) * 2012-11-13 2018-05-24 ナント ホールディングス アイピー，エルエルシー カルシウムフラックスアゴニスト及びその方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113144197A (zh) * 2013-02-08 2021-07-23 罗达制药公司 治疗局部微生物感染的方法
US9884087B1 (en) * 2013-05-03 2018-02-06 Chan Soon-Shiong Nanthealth Foundation Compositions and methods of improved wound healing
US10105305B2 (en) * 2014-02-19 2018-10-23 The Johns Hopkins University Compositions and methods for promoting skin regeneration and hair growth
CN108700566A (zh) * 2016-02-19 2018-10-23 河谷控股Ip有限责任公司 免疫原性调节的方法
JP6595746B2 (ja) * 2016-09-19 2019-10-23 フラー・ラボラトリーズ バベシア・ミクロチのインビトロ増殖
CN107496420B (zh) * 2017-08-25 2020-07-07 中国科学院微生物研究所 环匹阿尼酸类生物碱化合物的用途
US11969402B2 (en) 2019-05-16 2024-04-30 The Johns Hopkins University Compositions and methods for skin rejuvenation
CN111840560B (zh) * 2020-07-24 2021-09-03 广州医科大学 钙离子载体在白癜风治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960667A (en) 1972-03-23 1976-06-01 Eli Lilly And Company Antibiotic A23187 and process for preparation thereof
US3873693A (en) 1974-03-11 1975-03-25 Squibb & Sons Inc Ionomycin
US5489441A (en) * 1992-01-07 1996-02-06 Procept, Inc. Method for suppressing immune response associated with psoriasis, contact dermatitis and diabetes mellitus
US5238689A (en) * 1992-01-07 1993-08-24 Procept, Inc. Use of ruthenium red as immunosuppressive agents
TWI268153B (en) * 2004-06-23 2006-12-11 Univ Nat Cheng Kung A medicine composition for increasing leukocyte immunity wherein a leukocyte treated by sarcoplasmic/endoplasmic reticulum Ca2+ ATPase
GB0505909D0 (en) * 2005-03-23 2005-04-27 Univ Leeds Formulations
US20070111936A1 (en) * 2005-11-15 2007-05-17 Vladimir Pak Complex of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
US20080160116A1 (en) * 2006-12-07 2008-07-03 Herbalscience Singapore Pte. Ltd Compositions and Methods Comprising Zingiber Species
US20100105644A1 (en) * 2008-10-27 2010-04-29 The Regents Of The University Of Michigan Botanical composition for enhanced skin repair and uses thereof
CA2783244A1 (en) 2009-12-07 2011-06-16 Momentum Technologies, Inc. Nutrient yielding bio-renewable controlled release fertilizer coatings
WO2011115970A1 (en) 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania System and method of preparing and storing activated mature dendritic cells
WO2012054792A2 (en) * 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018080199A (ja) * 2012-11-13 2018-05-24 ナント ホールディングス アイピー，エルエルシー カルシウムフラックスアゴニスト及びその方法

Also Published As

Publication number Publication date
JP2015537000A (ja) 2015-12-24
WO2014078447A1 (en) 2014-05-22
KR20150140625A (ko) 2015-12-16
EP2919793B1 (en) 2020-05-06
CN105188716B (zh) 2019-02-22
JP6625677B2 (ja) 2019-12-25
EP2919793A4 (en) 2016-06-01
US20170128568A1 (en) 2017-05-11
US20150297572A1 (en) 2015-10-22
KR20190038679A (ko) 2019-04-08
US9750805B2 (en) 2017-09-05
KR20170126031A (ko) 2017-11-15
AU2013344879B2 (en) 2016-04-28
CN105188716A (zh) 2015-12-23
US20170360925A1 (en) 2017-12-21
CA2893276C (en) 2017-04-18
EP2919793A1 (en) 2015-09-23
CA2893276A1 (en) 2014-05-22
JP2018080199A (ja) 2018-05-24
US9463184B2 (en) 2016-10-11

Similar Documents

Publication Publication Date Title
JP6280129B2 (ja) カルシウムフラックスアゴニスト及びその方法
AU2012219321B2 (en) Compositions comprising peroxy alpha-ketocarboxylic acid and methods for producing and using the same
JP6944399B2 (ja) プロバイオティクス細菌
US10434142B2 (en) Compositions and methods of improved wound healing
AU2013344879A1 (en) Calcium flux agonists and methods therefor
CN101808627A (zh) 抗菌剂
Yang et al. EGCG induces pro-inflammatory response in macrophages to prevent bacterial infection through the 67LR/p38/JNK signaling pathway
Goswami et al. Effect of human placental extract in the management of biofilm mediated drug resistance–A focus on wound management
El-Hamid et al. Silver nanoparticles loaded with pomegranate peel extract and hyaluronic acid mediate recovery of cutaneous wounds infected with Candida albicans
Ranjbar et al. Effects of curcumin and Its analogues on infectious diseases
Ye et al. Esc‐1GN shows therapeutic potentials for acne vulgaris and inflammatory pain
RU2636523C1 (ru) Лекарственное средство для ускорения заживления ран, содержащее хлорид рубидия в виде порошка
Yates Time-kill kinetics of a novel antimicrobial silver wound gel against select wound pathogens
WO2017127830A1 (en) Anti-neutrophil activity on innate immune response
RU2629596C1 (ru) Порошкообразный препарат с антибактериальным и регенерирующим эффектами

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20150710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171130

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171226

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180118

R150 Certificate of patent or registration of utility model

Ref document number: 6280129

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250